![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/asset/a5db3686-c528-4236-93cf-6855cbd7db92/gr1.jpg)
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
![Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/cb26e910-dc14-4b32-a123-110b22c44f1e/gr1.jpg)
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine
![Vaccines | Free Full-Text | Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study Vaccines | Free Full-Text | Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study](https://www.mdpi.com/vaccines/vaccines-10-01914/article_deploy/html/images/vaccines-10-01914-g001.png)
Vaccines | Free Full-Text | Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study
![Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/21aefd8d-1880-42db-8338-92a386a5842f/gr1.jpg)
Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases
![Volunteers in Wrexham needed for world-first COVID-19 vaccine booster study - Betsi Cadwaladr University Health Board Volunteers in Wrexham needed for world-first COVID-19 vaccine booster study - Betsi Cadwaladr University Health Board](https://emedia1.nhs.wales/BCUhb/cache/file/1358FE16-55DF-4AEC-B3B8DF3942BF95C6_carouselimage.jpg)
Volunteers in Wrexham needed for world-first COVID-19 vaccine booster study - Betsi Cadwaladr University Health Board
![World first COVID-19 vaccine booster study launches in NHS Greater Glasgow and Clyde | NHS Research Scotland | NHS Research Scotland World first COVID-19 vaccine booster study launches in NHS Greater Glasgow and Clyde | NHS Research Scotland | NHS Research Scotland](https://www.nhsresearchscotland.org.uk/uploads/images/contentheader/1621449649VaccinationPPE1251663430.jpg)
World first COVID-19 vaccine booster study launches in NHS Greater Glasgow and Clyde | NHS Research Scotland | NHS Research Scotland
![Comparative Effectiveness of Pfizer and Moderna COVID-19 Vaccines for Boosting | Bennett Institute for Applied Data Science Comparative Effectiveness of Pfizer and Moderna COVID-19 Vaccines for Boosting | Bennett Institute for Applied Data Science](https://www.bennett.ox.ac.uk/blog/2023/04/comparative-effectiveness-of-pfizer-and-moderna-covid-19-vaccines-for-boosting/parang-mehta-r2fqXao_z70-unsplash_hu3d03a01dcc18bc5be0e67db3d8d209a6_1606091_d9f81c10174e45b769348a4ec206d95a.jpg)
Comparative Effectiveness of Pfizer and Moderna COVID-19 Vaccines for Boosting | Bennett Institute for Applied Data Science
![DPH Shares Monthly COVID-19 Update, Announces Changes to Data Reporting and Booster Guidance - State of Delaware News DPH Shares Monthly COVID-19 Update, Announces Changes to Data Reporting and Booster Guidance - State of Delaware News](https://news.delaware.gov/files/2022/12/DPH-Shares-Monthly-COVID19-Update-Announces-Changes-to-Data-Reporting-and-Booster-Guidance-Highlights-Vaccine-Effectiveness-Study.png)
DPH Shares Monthly COVID-19 Update, Announces Changes to Data Reporting and Booster Guidance - State of Delaware News
![Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-02031-7/MediaObjects/41591_2022_2031_Fig1_HTML.png)
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
![Get Boosted: New Study Underscores Need for COVID-19 Booster Shots for Older Adults | Johns Hopkins Medicine Get Boosted: New Study Underscores Need for COVID-19 Booster Shots for Older Adults | Johns Hopkins Medicine](https://www.hopkinsmedicine.org/-/media/images/newsreleases/2022/09/kristen-getty-image.jpeg)
Get Boosted: New Study Underscores Need for COVID-19 Booster Shots for Older Adults | Johns Hopkins Medicine
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/55458d8a-6e53-43a3-abb0-e72e5acba138/gr1.gif)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/asset/317ba83b-0864-4f92-bfd5-473f45a92e43/gr1.gif)